ClinicalTrials.gg
RecruitingNCT05295498Updated Oct 10, 2024

Analgesic Effect of Accelerated Repetitive Transcranial Magnetic Stimulation in Neuropathic Pain

An interventional study of Active repetitive transcranial magnetic stimulation and Sham repetitive transcranial magnetic stimulation in Peripheral Neuropathy, sponsored by Jakub Antczak. Recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-10.

Primary conditionNeuralgiaRegistry: Peripheral Nervous System DiseasesReclassifiedWhy we changed it
Registry
Peripheral Nervous System Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Neuralgia
Why
  1. The study's title name Neuralgia, a narrower term within Peripheral Nervous System Diseases.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Jakub Antczak · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Neuralgia with a site in Poland — 4 open to participants now, 5 under way, none of them phase 3. Neuralgia · Poland.

Planned enrollment
23rd of 25
70 · median 142
Started
2022
with 1 other
No phase
5 of 27
3 open now
Registered
21st of 27
by date

Among the 27 studies in Neuralgia with a site in Poland, this one is the 23rd largest by planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2022, is one of 5 with no phase, and was the 21st registered.

Neuralgia

1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.

Browse Neuralgia studies →

Open to participants now

4 of the 27 studies in Neuralgia with a site in Poland are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 155 Neuralgia studies recruiting now, 79 (51%) set no upper age limit and 44 (28%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Neuralgia with a site in Poland, or all of them as a file.
02

Study summary

Peripheral neuropathy is a frequent condition, commonly associated with pain. Repetitive Transcranial Magnetic Stimulation (rTMS) is a noninvasive method of modulation of brain plasticity and is regarded as one of alternative methods to alleviate pain associated with various kind of neuropathies. rTMS is usually performed once a day and the whole therapy of neuropathic pain lasts one week. In a number of recent clinical trials including patients with depression and some other disorders, rTMS was delivered several times a day, which reduced the time of the whole therapy. This approach was termed an accelerated rTMS. The purpose of this study is to investigate feasibility of accelerated rTMS in treatment of neuropathic pain.

Read the detailed description

Peripheral neuropathy is a frequent condition, commonly associated with pain, which is often drug resistant. Repetitive Transcranial Magnetic Stimulation (rTMS) is a noninvasive method of modulation of brain plasticity. In this method, series of magnetic stimuli are delivered to the cerebral cortex, where they turn to electric current and depolarize repetitively the targeted neurons. If the stimulation is repeated during subsequent days it is capable to modify the activity of targeted cortical area for weeks or even months and by this way to achieve therapeutic effect. rTMS is most commonly used to treat drug-resistant depression but a number of other psychiatric and neurologic conditions is increasingly being regarded as therapeutic indication for rTMS. In patients suffering from neuropathic pain rTMS is delivered with high frequency, over primary motor areas (PMA). Stimulation of PMA should result in modulation of thalamic activity, achieved by antidromic excitation of thalamocortical connections. rTMS is usually performed once a day and the whole therapy of neuropathic pain lasts one week. In a number of recent clinical trials including patients with depression and some other disorders, rTMS was delivered several times a day, which reduced the time of the whole therapy. This approach was termed an accelerated rTMS. The purpose of this study is to investigate feasibility of accelerated rTMS in treatment of neuropathic pain.

03

Conditions studied

  • Peripheral Neuropathy

Browse trials for

Keywords

  • Peripheral neuropathy
  • Neuropathic pain
  • rTMS
  • analgesic effect
04

In context

Neuralgia Reclassified

1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.

This study's planned enrollment of 70 is above the median of 52 across 833 interventional studies indexed under Neuralgia.

Browse Neuralgia studies →

Lead sponsor

Jakub Antczak is the lead sponsor of 8 studies on the registry; 5 are open to participants now.

Compared within Neuralgia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Peripheral Nervous System Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of peripheral neuropathy
  • Neuropathic pain of constant severity since not less than a month and requiring use of analgesics more than once a week
  • Score of 30 millimeter or more on the 100 millimeter visual analog scale of pain intensity at inclusion

Exclusion criteria

Exclusion Criteria:

  • Severe depression
  • Personality disorders and other psychiatric conditions, which could disturb the participation in the study
  • Cognitive deficits, which could disturb the participation in the study
  • Epilepsy
  • Presence of magnetic material in the reach of magnetic field
  • Pregnancy
  • Likelihood to get pregnant
  • Intracranial electrodes
06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Active repetitive transcranial magnetic stimulation

    10 hertz (Hz) rTMS will be administered over the primary motor area. Therapy will include 6 sessions (three sessions in two consecutive days). In every sessions 1500 magnetic pulses of 90% of the resting motor threshold intensity will be elicited.

    Device: Active repetitive transcranial magnetic stimulation

  • Sham comparator
    Sham repetitive transcranial magnetic stimulation

    Sham stimulation will mimic the active one except that the stimulating coil will be held perpendicularly to the scalp, which assures similar impression as the active stimulation but prevents that significant magnetic field will reach brain tissue.

    Device: Sham repetitive transcranial magnetic stimulation

Interventions

  • DeviceActive repetitive transcranial magnetic stimulation

    High frequency rTMS over the primary motor area to induce the long term potentiation of primary motor areas for the muscles of upper extremity.

  • DeviceSham repetitive transcranial magnetic stimulation

    Sham stimulation to mimic the high frequency rTMS over the primary motor area.

07

What researchers measure

Primary outcomes

  1. Visual Analogue Scale of Pain Severity after rTMS

    An analog scale of the length of 100 millimeter. Total score of 100, with higher scores representing more severe pain. Change from baseline score in the Visual Analogue Scale to the measurement taken after finishing rTMS.

    Time frame: Through study completion, an average of 1 year.

  2. Visual Analogue Scale of Pain Severity First Follow-up

    An analog scale of the length of 100 millimeter. Total score of 100, with higher scores representing more severe pain. Change from baseline score in the Visual Analogue Scale to the measurement taken after two weeks after finishing rTMS.

    Time frame: Before rTMS, up to one day after finishing rTMS.

  3. Visual Analogue Scale of Pain Severity Second Follow-up

    An analog scale of the length of 100 millimeter. Total score of 100, with higher scores representing more severe pain. Change from baseline score in the Visual Analogue Scale to the measurement taken after four weeks after finishing rTMS.

    Time frame: Before rTMS, four weeks after finishing rTMS.

Secondary outcomes

  1. Numeric Pain Severity Scale after rTMS

    Total score 10, with higher scores representing more severe pain. Change from baseline score in the Numeric Pain Severity Scale to the measurement taken after finishing rTMS.

    Time frame: Before rTMS, up to one day after finishing rTMS.

  2. Numeric Pain Severity Scale First Follow-up

    Total score 10, with higher scores representing more severe pain. Change from baseline score in the Numeric Pain Severity Scale to the measurement taken two weeks after finishing rTMS.

    Time frame: Before rTMS, two weeks after finishing rTMS.

  3. Numeric Pain Severity Scale Second Follow-up

    Total score 10, with higher scores representing more severe pain. Change from baseline score in the Numeric Pain Severity Scale to the measurement taken after four weeks after finishing rTMS.

    Time frame: Before rTMS, four weeks after finishing rTMS.

  4. Neuropathic Pain Symptoms Inventory after rTMS

    Total score 120, with higher scores representing more severe pain and other symptoms of neuropathy. Change from baseline score in the Neuropathic Pain Symptoms Inventory to the measurement taken after finishing rTMS.

    Time frame: Before rTMS, up to one day after finishing rTMS.

  5. Neuropathic Pain Symptoms Inventory First Follow-up

    Total score 120, with higher scores representing more severe pain and other symptoms of neuropathy. Change from baseline score in the Neuropathic Pain Symptoms Inventory to the measurement taken two weeks after finishing rTMS.

    Time frame: Before rTMS, two weeks after finishing rTMS.

  6. Neuropathic Pain Symptoms Inventory Second Follow-up

    Total score 120, with higher scores representing more severe pain and other symptoms of neuropathy. Change from baseline score in the Neuropathic Pain Symptoms Inventory to the measurement taken four weeks after finishing rTMS.

    Time frame: Before rTMS, four weeks after finishing rTMS.

  7. Athens Insomnia Scale after rTMS

    Total score 24, with higher scores representing more severe insomnia. Change from baseline score in the Athens Insomnia Scale to the measurement taken after finishing rTMS.

    Time frame: Before rTMS, up to one day after finishing rTMS.

  8. Athens Insomnia Scale First Follow-up

    Total score 24, with higher scores representing more severe insomnia. Change from baseline score in the Athens Insomnia Scale to the measurement taken two weeks after finishing rTMS.

    Time frame: Before rTMS, two weeks after finishing rTMS.

  9. Athens Insomnia Scale Second Follow-up

    Total score 24, with higher scores representing more severe insomnia. Change from baseline score in the Athens Insomnia Scale to the measurement taken four weeks after finishing rTMS.

    Time frame: Before rTMS, four weeks after finishing rTMS.

  10. Bilateral Dynamometric Assessment of the strength of the foot extension after rTMS

    Change from baseline strength of the foot extension to the measurement taken after finishing rTMS.

    Time frame: Before rTMS, up to one day after finishing rTMS.

  11. Bilateral Dynamometric Assessment of the strength of the foot extension First Follow-up

    Change from baseline strength of the foot extension to the measurement taken two weeks after finishing rTMS.

    Time frame: Before rTMS, two weeks after finishing rTMS.

  12. Bilateral Dynamometric Assessment of the strength of the foot extension Second Follow-up

    Change from baseline strength of the foot extension to the measurement taken four weeks after finishing rTMS.

    Time frame: Before rTMS, four weeks after finishing rTMS.

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: Yes — After completing the study, the age and gender of participants as well as the scores and results of all outcome measurements made at baseline, after rTMS, at the first and at the second follow-up will be made available to other researchers on request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: The data will become available after the study results will be published.

Access criteria: On request sent by e-mail to jakub.antczak@uj.edu.pl

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Mar 2026, 40 months after the start.

Of 249 non-industry interventional studies with no phase under Neuralgia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's planned 40 months is above that.

Counting every sponsor, half of 267 studies reached it within 24 months; a quarter within 10 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2022
First posted
Mar 25, 2022
StartActual
Nov 4, 2022
Primary completionEst.
Mar 31, 2026
CompletionEst.
Sep 30, 2026
Last update
Oct 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05295498
Lead sponsor
Jakub Antczak
Responsible party
Jakub Antczak (Principal Investigator, Jagiellonian University) — Sponsor-investigator
First posted
Mar 25, 2022
Start date
Nov 4, 2022
Primary completion
Mar 31, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Oct 10, 2024

Study contacts

Jakub M Antczak, MD
Contact
jakub.antczak@uj.edu.pl
+48 795 421 153
Gabriela G Rusin, MD
Contact
gabriela.rusin@doctoral.uj.edu.pl
+48 601 661 607
Tomasz Klupa, Professor
study chair · Jagiellonian University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion